What are peripheral artery disease symptoms?

PAD symptoms range from asymptomatic (most common — ~50% of ABI <0.9 patients have no classic symptoms) to: Claudication — reproducible exertional leg pain (usually calf pain) that resolves with rest within 10 minutes; Atypical exertional leg symptoms (weakness, heaviness, aching); Rest pain — severe burning pain in the foot at rest, especially at night, relieved by hanging foot down (gravity-assisted perfusion); Non-healing foot ulcers or gangrene — critical limb ischemia. The Fontaine classification grades PAD from I (asymptomatic) to IV (ulceration/gangrene).

What are the treatment implications of an abnormal ABI?

ABI <0.9 (PAD diagnosed): (1) Antiplatelet therapy: aspirin or clopidogrel (clopidogrel preferred per CAPRIE); (2) High-intensity statin regardless of LDL level (LDL target <70 mg/dL); (3) Blood pressure control (ACE inhibitor or ARB preferred); (4) Smoking cessation (most impactful modifiable risk factor — reduces PAD progression and CV events); (5) Supervised exercise program (first-line for claudication); (6) Diabetes optimization; (7) Cilostazol for claudication symptoms; (8) Revascularization for lifestyle-limiting claudication or critical limb ischemia.

What is the difference between claudication and critical limb ischemia?

Claudication: exertional leg pain (typically calf muscles) that occurs with walking a reproducible distance and resolves within 10 minutes of rest. ABI typically 0.5-0.8. Treated initially with supervised exercise, medical therapy, and risk factor modification. Critical limb ischemia (CLI): severe ischemia at rest causing rest pain and/or non-healing wounds/ulcers/gangrene. ABI typically 30% 1-year amputation rate without revascularization. 1-year mortality of CLI patients: ~20%.

Should antiplatelet therapy be given for PAD?

Antiplatelet therapy is recommended for symptomatic PAD per ACC/AHA 2016 PAD Guidelines: aspirin 75-325 mg daily OR clopidogrel 75 mg daily. Clopidogrel has superior evidence for PAD specifically (CAPRIE trial: 23.8% relative risk reduction vs. aspirin for PAD primary endpoint). For asymptomatic PAD (ABI <0.9 without symptoms), aspirin is reasonable (Class IIa recommendation). Dual antiplatelet therapy (aspirin + clopidogrel) is not recommended for stable claudication but is used for 1-12 months after PAD endovascular intervention (stenting).

What is supervised exercise therapy for claudication?

Supervised exercise rehabilitation is the most effective initial treatment for claudication. Programs consist of: treadmill walking at an intensity that induces mild-moderate claudication (usually 3.5 km/h at 10-12% grade), continuing until pain intensity of 3-4/10, then resting until pain subsides and repeating. Sessions are 30-45 minutes, 3 times per week, for 12 weeks minimum. Results: average 100-150% improvement in pain-free and maximum walking distance. It is a Class I recommendation before revascularization for stable claudication in ACC/AHA and ESC PAD guidelines.

When should ABI screening be performed?

ACC/AHA 2016 PAD Guidelines recommend ABI testing for: all patients with exertional leg symptoms (claudication); all patients aged ≥65 regardless of symptoms; patients aged 50-64 with diabetes, smoking history, or other PAD risk factors; patients with abnormal lower extremity pulse exam; patients with non-healing wounds of the foot or leg; patients with known coronary or carotid artery disease (high PAD co-prevalence). ABI is also recommended as a risk-enhancing factor evaluation in intermediate-risk patients (7.5-20% 10-year ASCVD risk) per ACC/AHA 2019 Cholesterol Guidelines.

What is toe-brachial index (TBI) and when is it used?

Toe-brachial index (TBI) measures systolic toe pressure divided by brachial pressure using small pneumatic toe cuffs and photoplethysmography (PPG) or laser Doppler. Normal TBI ≥0.7. TBI 1.4 (calcified arteries in diabetes/CKD — TBI is more reliable than ABI); ABI result is inconsistent with clinical presentation; wound healing assessment (TBI >0.6 generally required for wound healing). TBI is more sensitive than ABI for digital ischemia and is the recommended test in diabetic patients with suspected PAD.

Online Medical Tools — Ankle-Brachial Index

Printed on 9/3/2026

For informational purposes only. This is not medical advice.

Cardiology

Ankle-Brachial Index

Ankle-Brachial Index (ABI) compares ankle systolic pressure to brachial systolic pressure. It is a simple non-invasive vascular screening metric used to identify probable peripheral artery disease and stratify ischemic severity patterns.

Formula: ABI = ankle systolic pressure / brachial systolic pressure.

Ankle systolic pressure

mmHg

Brachial systolic pressure

mmHg

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Measure bilateral brachial and ankle systolic pressures

Patient should rest supine for 5-10 minutes. Using a hand-held Doppler probe (8-10 MHz) and blood pressure cuff, measure systolic blood pressure at four locations: both brachial arteries (arms), and both posterior tibial and dorsalis pedis arteries at the ankles. Record all six systolic values. A standard automatic blood pressure cuff alone is significantly less accurate and should not substitute for hand-held Doppler.

Calculate ABI for each leg separately

For each leg, ABI = highest ankle pressure (whichever is greater: posterior tibial or dorsalis pedis) divided by the highest brachial pressure (either arm). Calculate separately for the right leg and left leg. Example: right ankle highest = 110 mmHg, highest brachial = 130 mmHg: right ABI = 110/130 = 0.85 (mild PAD). The lower ABI of the two legs determines overall PAD severity.

Interpret ABI values for PAD diagnosis and severity

Normal ABI 1.0-1.4. Borderline 0.91-0.99 (possible early PAD, re-evaluate with exercise ABI). Mild PAD 0.71-0.90. Moderate PAD 0.41-0.70. Severe PAD ≤0.40 (critical limb ischemia, limb threat). ABI >1.4: non-compressible arteries (calcification — common in diabetes, CKD, elderly) — falsely elevated, use toe-brachial index (TBI) instead. An abnormal ABI in any category warrants referral for vascular assessment and intensified cardiovascular risk factor management.

Who Uses the Ankle-Brachial Index

PAD Diagnosis and Severity Classification

Vascular surgeons, cardiologists, primary care physicians, podiatrists

ABI <0.9 is diagnostic for PAD with sensitivity 79% and specificity 96% versus arteriography (Fowkes et al.). ABI provides a non-invasive, office-based screening test to confirm PAD in patients with claudication, atypical leg symptoms, non-healing wounds, or abnormal vascular exam findings.

Cardiovascular Risk Marker and ASCVD Risk Enhancement

Cardiologists, preventive medicine physicians, primary care physicians

ABI <0.9 is a major atherosclerotic cardiovascular disease (ASCVD) risk-enhancing factor per ACC/AHA 2019 Cholesterol Guidelines (Grundy et al., Circulation 2019). Abnormal ABI predicts 2-4 times increased risk of MI and stroke. It should intensify statin therapy and blood pressure management decisions in intermediate-risk patients.

Screening High-Risk Populations for PAD

Primary care physicians, diabetes care teams, vascular clinics

ABI screening is recommended for: patients aged >50 with diabetes or smoking history; patients aged >70 regardless of symptoms; patients with exertional leg symptoms or non-healing foot wounds. Early PAD detection prevents limb loss and identifies patients who need aggressive cardiovascular risk factor management.

Monitoring PAD Progression and Treatment Response

Vascular surgeons, interventional cardiologists, vascular medicine physicians

Serial ABI measurements track disease progression over time and monitor response to interventions (angioplasty, bypass surgery, supervised exercise programs). Post-procedure ABI improvement confirms successful revascularization. Declining ABI over time documents progressive disease requiring escalation of medical or interventional therapy.

Evaluating Claudication and Critical Limb Ischemia

Vascular surgeons, emergency physicians, wound care specialists

ABI quantifies ischemia severity in patients with claudication or rest pain. Claudication typically occurs at ABI 0.5-0.8; critical limb ischemia (rest pain, non-healing ulcers, gangrene) at ABI <0.4. This grading guides urgency of revascularization — critical limb ischemia requires urgent intervention to prevent amputation.

Pro Tips

Hand-held Doppler is required — automatic cuffs are not adequate

ABI requires a hand-held Doppler probe (8-10 MHz) to detect ankle systolic pressures accurately. Standard automatic blood pressure cuffs significantly overestimate ankle pressures in atherosclerotic vessels and underperform in calcified arteries. The Doppler technique allows the examiner to identify the disappearance and return of Doppler signal precisely, providing accurate systolic pressure measurement even in diseased vessels.

ABI <0.9 is diagnostic for PAD — sensitivity 79%, specificity 96%

An ABI <0.9 in either leg diagnoses PAD with high specificity (96%) versus digital subtraction arteriography as the gold standard (Fowkes et al., Int Angiol 1992). Sensitivity of 79% means ~21% of PAD patients may be missed by resting ABI (particularly those with single-vessel disease or mild PAD). Positive ABI findings should prompt immediate PAD management. Negative ABI in a symptomatic patient should prompt exercise ABI testing.

ABI >1.4 = non-compressible arteries — does NOT indicate normal vessels

An ABI >1.4 indicates medial artery calcification — stiff, non-compressible arteries that maintain high pressure despite luminal narrowing. This pattern is common in diabetes, CKD, and elderly patients. ABI >1.4 is falsely reassuring and does NOT exclude PAD. These patients require toe-brachial index (TBI) using toe cuffs, since digital arteries are less affected by medial calcification. A TBI <0.7 indicates significant PAD in this setting.

Abnormal ABI is a major ASCVD risk enhancer — intensify cardiovascular risk factor management

ABI <0.9 predicts 2-4 times increased cardiovascular event risk (MI, stroke, CV death). Per ACC/AHA 2019 Cholesterol Guidelines, ABI <0.9 is a major risk-enhancing factor for statin therapy decisions in intermediate-risk patients (7.5-20% 10-year ASCVD risk). Abnormal ABI should intensify LDL lowering (target LDL <70 mg/dL or <55 mg/dL in very high risk), blood pressure control, smoking cessation, and diabetes management.

Exercise ABI: if resting ABI is 0.91-1.4 but symptoms are present

Some patients with PAD have near-normal resting ABI but develop ischemia with exertion (exercise-induced PAD). Exercise treadmill ABI: measure resting ABI, have patient walk on treadmill (3.5 km/h, 12% grade) until claudication or 5 minutes, then immediately remeasure ankle pressures. A >20% drop in ABI post-exercise versus baseline is diagnostic for hemodynamically significant PAD. This test is particularly valuable for patients with atypical symptoms.

PAD patients have ~30% 5-year cardiovascular mortality risk

PAD is a powerful marker of systemic atherosclerosis — not just peripheral disease. Patients with PAD have approximately 30% 5-year cardiovascular mortality risk and similar rates of MI and stroke (TASC II Working Group). PAD should be treated as a cardiovascular disease equivalent — the same aggressive secondary prevention as post-MI patients: high-intensity statin, blood pressure control, smoking cessation, antiplatelet therapy, and regular follow-up.

Supervised exercise is first-line treatment for claudication

Supervised exercise rehabilitation is the most effective treatment for claudication — improving walking distance by >100% more than cilostazol and more than unsupervised walking (McDermott et al., JAMA 2013; Gardner et al., JAMA 2000). Programs consist of 30-45 minutes of treadmill walking at claudication threshold, 3 times per week, for 12 weeks. It is recommended as a Class I indication in ACC/AHA 2016 PAD Guidelines before considering revascularization for claudication.

Antiplatelet therapy is indicated for symptomatic PAD

Antiplatelet therapy (aspirin 75-325 mg daily OR clopidogrel 75 mg daily) is recommended for symptomatic PAD per ACC/AHA 2016 PAD Guidelines. Clopidogrel has slightly better evidence than aspirin for PAD specifically (CAPRIE trial: 23.8% relative risk reduction vs. aspirin for PAD subgroup). Dual antiplatelet therapy is not standard for stable claudication but is used after PAD intervention. Aspirin alone is reasonable for asymptomatic PAD with ABI <0.9.

Measure BOTH legs and record ABI separately

Always measure ABI in both legs. PAD may be asymmetric — one leg may have critical ischemia while the other is normal. The lower ABI of the two legs determines overall PAD severity for management decisions. Comparing bilateral ABIs also helps detect mid-aortic occlusive disease (bilateral equal reduction in ABI) vs. unilateral iliac or femoral disease (asymmetric ABI reduction).

Cilostazol is FDA-approved for claudication — phosphodiesterase inhibitor

Cilostazol 100 mg twice daily is FDA-approved for claudication and improves walking distance by approximately 50-70% in randomized trials. Mechanism: phosphodiesterase III inhibition causes arterial vasodilation and antiplatelet effects. Contraindicated in heart failure with any reduced EF. Alternatives: naftidrofuryl (available in Europe, superior to cilostazol in some meta-analyses). Medical therapy should be combined with supervised exercise, not used as a substitute.

Common Questions About Your Results

ABI >1.4 indicates non-compressible, calcified arteries that cannot be compressed by the blood pressure cuff. When arteries cannot be compressed, the measured pressure is falsely high — the cuff reads 'normal' or 'high' pressure despite possible significant narrowing of the arterial lumen. This pattern is most common in diabetes, CKD, and elderly patients who already have high PAD prevalence. ABI >1.4 requires toe-brachial index (TBI) measurement — digital arteries are usually less calcified and provide a more accurate assessment of distal perfusion.

Automatic oscillometric blood pressure cuffs are significantly less accurate than hand-held Doppler for ABI measurement. Oscillometric devices may be acceptable for initial screening in low-risk populations but have limited sensitivity for detecting PAD in patients with calcified or diseased vessels. ACC/AHA guidelines and vascular society standards recommend hand-held Doppler for definitive ABI measurement. If ABI by automatic device is borderline (0.9-1.1), confirm with Doppler technique.

In diabetic patients, interpreting ABI is more complex because of medial artery calcification. An ABI of 0.91-1.4 should not be assumed normal in a diabetic patient with foot symptoms, non-healing wounds, or diminished pulses. ABI >1.4 strongly suggests calcification and requires TBI measurement (normal TBI ≥0.7). Many guidelines recommend checking TBI alongside ABI in all diabetic patients with foot complications, as ABI may miss significant ischemia in calcified vessels.

ABI measurement is painless and entirely non-invasive — it involves standard blood pressure cuff inflation and Doppler probe placement, similar to a routine BP check. The procedure carries no risks and requires no radiation, contrast, or needles. The test takes approximately 15-30 minutes to measure all four limb pressures. Patients with severe critical limb ischemia may experience discomfort during cuff inflation of the affected limb, but the procedure is safe.

After confirming PAD with ABI <0.9, further vascular imaging is indicated when: (1) considering revascularization (bypass or angioplasty) for lifestyle-limiting claudication unresponsive to supervised exercise and medical therapy; (2) critical limb ischemia (ABI <0.4, rest pain, or non-healing wounds) requiring urgent revascularization planning; (3) ABI is borderline (0.9-0.99) with strong clinical symptoms; (4) the ABI cannot reliably assess disease location (duplex ultrasound maps stenosis segment, CTA provides anatomical roadmap for revascularization planning).

Evidence-Based Methodology

ABI reference ranges and PAD diagnosis: Hirsch et al. (Circulation 2006, ACC/AHA PAD Guidelines). ABI sensitivity 79%, specificity 96% vs. arteriography: Fowkes et al. (Int Angiol 1992). ABI <0.9 predicts 2× MI risk: Fowkes et al. (JAMA 2008, n=400,000 systematic review). ABI as ASCVD risk enhancer: Grundy et al. (Circulation 2019, ACC/AHA Cholesterol Guidelines). Supervised exercise for claudication: Gardner et al. (JAMA 2000), McDermott et al. (JAMA 2013). Cilostazol for claudication: Thompson et al. (Am J Cardiol 2002). ACC/AHA 2016 PAD Guidelines: Gerhard-Herman et al. (JACC 2017). CAPRIE antiplatelet trial in PAD: CAPRIE Steering Committee (Lancet 1996).

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Lower ABI values generally indicate worse lower-extremity arterial perfusion and higher PAD likelihood.

When to Use This Tool

Use in suspected claudication, vascular risk assessment, diabetes/smoking populations, and baseline PAD screening workflows.

Limitations

ABI may be unreliable with arterial calcification (for example, in diabetes or CKD), requiring toe-brachial or duplex-based follow-up.

For related assessments, see ASCVD Risk Calculator, Framingham Risk and Blood Pressure Calculator.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Cardiology

ASCVD Risk Calculator

Estimate 10-year ASCVD risk using the 2013 ACC/AHA Pooled Cohort Equations, with the risk thresholds from the 2018 AHA/ACC cholesterol guideline.

Open Cardiology

Framingham Risk

Calculate 10-year cardiovascular disease risk with the Framingham Risk Score using age, cholesterol, blood pressure, smoking, and diabetes inputs.

Open Cardiology

Blood Pressure Calculator

Classify blood pressure readings into Normal, Elevated, Stage 1, Stage 2, or Hypertensive Crisis using ACC/AHA thresholds. Includes MAP and pulse pressure.

Open Cardiology

AIP Index

Calculate the Atherogenic Index of Plasma using triglycerides and HDL cholesterol to estimate atherogenic lipid risk.

Open

Frequently Asked Questions

The ankle-brachial index (ABI) is the ratio of ankle systolic blood pressure to arm (brachial) systolic blood pressure, measured using a hand-held Doppler probe. ABI = highest ankle pressure (posterior tibial or dorsalis pedis) divided by highest brachial pressure. It is the primary non-invasive test for diagnosing peripheral artery disease (PAD) and quantifying its severity. Normal ABI is 1.0-1.4. ABI <0.9 diagnoses PAD with 79% sensitivity and 96% specificity.

ABI interpretation: 1.0-1.4 = Normal; 0.91-0.99 = Borderline (possible early PAD, consider exercise ABI); 0.71-0.90 = Mild PAD (claudication possible); 0.41-0.70 = Moderate PAD (claudication usually present at short distances); ≤0.40 = Severe PAD / Critical limb ischemia (rest pain, non-healing wounds, gangrene risk). ABI >1.4 = Non-compressible arteries (calcified vessels in diabetes/CKD/elderly — requires toe-brachial index for accurate assessment).

ABI <0.9 in either leg is diagnostic for peripheral artery disease (PAD). This means the ankle arterial pressure is less than 90% of the arm pressure, indicating arterial narrowing from atherosclerosis in the leg arteries (usually aortoiliac or femoropopliteal segments). ABI <0.9 also predicts 2-4 times increased risk of major adverse cardiovascular events (MI, stroke, CV death) because PAD reflects systemic atherosclerosis. Antiplatelet therapy, statin therapy, blood pressure control, and smoking cessation are all indicated.

ABI measurement requires: (1) Doppler probe (8-10 MHz hand-held) and standard blood pressure cuffs. (2) Patient supine, resting for 5-10 min. (3) Measure systolic BP at both arms and both ankles (posterior tibial artery and dorsalis pedis artery at each ankle). (4) ABI = highest ankle pressure ÷ highest brachial pressure, calculated separately for each leg. (5) Interpret the lower of the two leg ABIs as the overall severity. The total procedure takes 15-30 minutes. Automatic BP cuffs are less accurate and not recommended for definitive ABI measurement.

Diabetes significantly complicates ABI interpretation due to medial artery calcification. Calcified arteries cannot be compressed by the BP cuff, producing falsely elevated ABI (often >1.4). In diabetic patients: ABI >1.4 does NOT indicate normal circulation — it indicates calcification, requiring toe-brachial index (TBI) measurement. ABI 0.9-1.4 should be interpreted cautiously in diabetics with foot symptoms. TBI <0.7 confirms significant PAD when ABI is unreliable. All diabetic patients with foot ulcers, non-healing wounds, or diminished pulses should have TBI alongside ABI.

ABI is a powerful systemic atherosclerosis marker. ABI <0.9 is associated with: 2× increased risk of MI (Fowkes et al., JAMA 2008, 400,000 participants), 3× increased risk of cardiovascular death, 5-year cardiovascular mortality of ~25-30%. ABI <0.9 is a major ASCVD risk-enhancing factor in ACC/AHA 2019 Cholesterol Guidelines — should intensify statin therapy decisions. PAD and coronary artery disease frequently coexist (30-50% of PAD patients have significant CAD). All PAD patients should be treated with cardiovascular risk factor management equivalent to secondary prevention post-MI.

Online Medical Tools — Ankle-Brachial Index

Ankle-Brachial Index

How It Works

Measure bilateral brachial and ankle systolic pressures

Calculate ABI for each leg separately

Interpret ABI values for PAD diagnosis and severity

Who Uses the Ankle-Brachial Index

PAD Diagnosis and Severity Classification

Cardiovascular Risk Marker and ASCVD Risk Enhancement

Screening High-Risk Populations for PAD

Monitoring PAD Progression and Treatment Response

Evaluating Claudication and Critical Limb Ischemia

Pro Tips

Hand-held Doppler is required — automatic cuffs are not adequate

ABI <0.9 is diagnostic for PAD — sensitivity 79%, specificity 96%

ABI >1.4 = non-compressible arteries — does NOT indicate normal vessels

Abnormal ABI is a major ASCVD risk enhancer — intensify cardiovascular risk factor management

Exercise ABI: if resting ABI is 0.91-1.4 but symptoms are present

PAD patients have ~30% 5-year cardiovascular mortality risk

Supervised exercise is first-line treatment for claudication

Antiplatelet therapy is indicated for symptomatic PAD

Measure BOTH legs and record ABI separately

Cilostazol is FDA-approved for claudication — phosphodiesterase inhibitor

Common Questions About Your Results

Evidence-Based Methodology

Clinical Content Trust

How to Interpret Your Result

When to Use This Tool

Limitations

Changelog

Related Tools

ASCVD Risk Calculator

Framingham Risk

Blood Pressure Calculator

AIP Index

Further Reading

A Complete Guide to Cardiology: Risk Scores, Heart Failure, and Cardiovascular Disease Management

Frequently Asked Questions